$647K
2 filings since 2025 · latest Equity filed
Paralos Bioscience is a pre-clinical stage biotechnology company spun out of UCLA developing phage-drug conjugates for targeted delivery of antibiotics to drug-resistant bacteria. Its platform uses engineered M13 bacteriophage as a programmable carrier, combining high drug loading, targeting specific bacterial pathogens, and manufacturing by E. coli fermentation. The company is a member of the Magnify Incubator at UCLA's California NanoSystems Institute and is focused on drug-resistant Gram-negative infections that drive sepsis and pneumonia in hospital settings.
What sets it apart
A modular phage conjugate system in which the targeting element and the drug payload can each be swapped independently, so one platform can be retargeted across pathogens and therapeutic payloads, while production runs on standard E. coli fermentation rather than a bespoke process.
A bacteriophage-based conjugation technology built on engineered M13 phage that carries antibiotic payloads and delivers them specifically to targeted bacterial pathogens.
